LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

An investigation by Democratic senators has raised concerns about conflicts of interest in telehealth companies' ties to pharmaceutical companies Pfizer and Eli Lilly.

PORTLAND, OR, UNITED STATES, July 17, 2025 /EINPresswire.com/ -- The global anti-obesity drugs market, valued at $1,605.36 million in 2022, is projected to reach $4,439.34 million by 2032, expanding ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Taking a page from Eli Lilly and Novo Nordisk, who have launched online programs to sell their diabetes and obesity drugs ...

In advance of CMS’ negotiated price for the blood thinner taking effect next year, partners Bristol Myers Squibb and Pfizer ...

Biopharmaceutical company Biocon is planning to submit a request for approval of generic copies of the blockbuster ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

DelveInsight's“ Obesity Pipeline Insigh t 2025 ” report provides comprehensive insights about 80+ companies and 100+ pipeline ...